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http:WHAT THIS PAPER ADDS
A novel endovascular technique for the management of abdominal aortic aneurysm (AAA) is assessed.
Morphological applicability is assessed in a range of patients who have undergone traditional infrarenal
endovascular aortic repair (EVR), open repair (OR), fenestrated endovascular repair (FEVR) or non-operative
management. The anatomical applicability of this new technology in these patients is assessed and
compared with other endograft devices currently in use. It is concluded that EVAS (Nellix) technology appears to
be widely applicable to contemporary infrarenal AAA practice, and provides an additional solution for patients
currently being treated by EVR outside current devices’ instructions for use.Objective: Endovascular aneurysm sealing (EVAS) using the Nellix system is a promising alternative to
endovascular repair (EVR) and open surgery for abdominal aortic aneurysms (AAA). The aim of this study was to
investigate the proportion of patients with AAA who are morphologically suitable for treatment with Nellix.
Methods: Patients presenting with AAA were investigated at two regionalised vascular units. Separate cohorts
were identiﬁed, who had undergone infrarenal EVR, open aneurysm repair, fenestrated endovascular repair
(FEVR) or non-operative management. Pre-operative morphology was quantiﬁed using three-dimensional
computed tomography according to a validated protocol. Each aneurysm was assessed for compliance with the
instructions for use (IFU) of Nellix
Results: 776 patients were identiﬁed with mean age 75  9 years. 730/776 (94.1%) had undergone infrarenal
EVR, 6/776 (0.8%) open repair, 27/776 (3.5%) FEVR and 13/776 (1.7%) had been managed non-operatively.
544/776 (70.1%) of all AAA were morphologically suitable for Nellix. 533/730 (73.0%) of patients who had
undergone infrarenal EVR were compliant with Nellix IFU, compared with 497/730 (68.1%), 379/730 (51.9%) and
214/730 (29.3%) with the IFU for Medtronic Endurant (p ¼ .04) or Cook Zenith (p < .01) and Gore C3 Excluder
(p < .01) endografts respectively.
Conclusions: Nellix technology appears widely applicable to contemporary infrarenal AAA practice, and may
provide an option for patients that are outside current EVR device instructions for use. However, formal
outcomes study is still required, and will ultimately dictate the clinical relevance of this feasibility study. The
major limitation to anatomic suitability for Nellix is currently the maximum patent lumen diameter of large AAA.
 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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The advent of endovascular aneurysm repair (EVR) has
permitted management of abdominal aortic aneurysm
(AAA) with signiﬁcantly lower perioperative risk than open
repair (OR). The long-term results of EVR are equivalent to
open repair,1 and continue to improve with increasing
experience, developing technology, and greater attention toresponding author. A. Karthikesalingam, St George’s Vascular Insti-
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//dx.doi.org/10.1016/j.ejvs.2013.06.017surveillance and reintervention.2 Patients prefer minimally
invasive surgery3 and EVR has supplanted open repair as the
most common management of AAA. However, aneurysm
morphology remains a key challenge for EVR, and is a key
determinant of long-term success.4,5 For each device,
manufacturers’ instructions for use (IFU) guide the operator
with regards to the limits of aneurysm morphology. Current
stent-grafts are often used outside IFU according to clinical
need, although this may be associated with a greater need
for secondary intervention.6 Close monitoring for aortic
complications (type 1 or 3 endoleak, device migration or sac
expansion) is mandatory.3,7
Adverse aneurysm morphology remains an important
obstacle to the universal use of EVR for AAA. The devel-
opment of fenestrated (FEVR) and branched devices has
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complex aneurysm morphology, with disease involving the
renal artery origins (suprarenal aneurysms) or coeliac and
superior mesenteric origins (Crawford type IV thoraco-
abdominal aneurysms). However, this technique is rela-
tively novel and technically challenging, while there remains
uncertainty regarding the optimum use of FEVR in juxtare-
nal (JRA), suprarenal (SRA), or type IV thoraco-abdominal
(TAA) aneurysms.8,9
The Nellix device10 employs a novel approach to AAA;
achieving aneurysm exclusion by EVAS (endovascular
aneurysm sealing). The device consists of two ﬂow channels
supported by bilateral balloon-expandable stents, with
surrounding EndoBags that are ﬁlled with a polymer solu-
tion that cures in situ. The polymer ﬁlling step is performed
under pressure monitoring until the EndoBags expand and
occupy the blood lumen space within the aneurysm sac,
allowing sealing of side branch ﬂow11 (Fig. 1). The expanded
polytetraﬂuoroethylene (ePTFE)-covered, cobalt chromium
(CoCr) alloy balloon-expandable stents provide biocompat-
ible structural support to the ﬂow lumens. The poly-
urethane EndoBags unwrap when ﬁlled with polymer
solution and conform to the aneurysm blood lumen to
provide sealing of the entire aortoiliac segment being
treated. The low viscosity polymer delivered to the Endo-
Bags is intended to form a biocompatible, biodurable, solid
polyethylene glycol (PEG)-based hydrogel in situ within
minutes of delivery. The 17Fr Nellix Catheter is compatible
with 0.03500 guidewires. After the system is advanced via
femoral artery access, the integrated catheter sheaths are
retracted, exposing the implants. The Nellix Accessory KitFigure 1. Nellix Endovascular device from http://www.endologix.
com/investigational_devices/nellix/.and Dispenser facilitate single-operator application of
bilateral Nellix Catheters. The Accessory Kit contains a
console, mixers and separately pouched Mirador Biomedical
Compass GP pressure transducer. Quick connectors on the
console allow for attachment to mating connectors on each
of the Nellix catheters. Ports on the console permit simul-
taneous management of the two catheters in the following
steps: (a) drawing a vacuum through the system to the
EndoBags, verifying EndoBag and ﬁll-line integrity, (b)
simultaneous balloon expansion of the stents, (c) intro-
duction of the mixed polymer solution under in-line pres-
sure monitoring to the EndoBags, and (d) angiography
performed through the catheter tips.
The IFU of this device allow greater morphological vari-
ability than those for the current generation of EVR stent-
grafts, potentially expanding the proportion of patients
with AAA that may be offered an endovascular solution.
However, it remains unknown whether this theoretical
advantage translates to clinical practice. The aim of this
study was to quantify the applicability of Nellix, by reporting
the proportion of patients presenting with AAA that were
morphologically suitable for treatment with the Nellix
device.
METHODS
Four patient groups were identiﬁed: patients who had un-
dergone EVR for infrarenal AAA (infrarenal EVR), open
aneurysm repair (OR) for infrarenal or juxtarenal AAA,
fenestrated endovascular repair (FEVR) for juxtarenal AAA,
and patients with AAA selected for non-operative
management.
Two prospectively maintained databases, which included
all patients undergoing EVR of infra-renal AAA, were inter-
rogated at two tertiary vascular centres. These databases
contained details of operative procedure, patient de-
mographics, comorbidity, and follow-up. Patients who had
undergone OR, FEVR, or non-operative management were
identiﬁed retrospectively at a single tertiary vascular centre
over differing time periods, and data regarding patient de-
mographics, comorbidity, and follow-up were collated.Inclusion criteria
All EVR for infrarenal AAA were studied at Leicester Royal
Inﬁrmary (LRI) and St George’s Vascular Institute (SGVI)
between January 2004 and June 2010. All cases of open
AAA repair and FEVR were studied at St George’s Vascular
Institute (SGVI) between January 2010 and July 2012. AAA
managed non-operatively at SGVI were studied between
January 2008 and January 2009. Different temporal cohorts
were chosen for convenience, based on the availability of
complete morphological data for existing databases and the
centre of treatment received by each group of patients.
Data collection and study design were adherent to recent
reporting standards for endovascular aneurysm repair.12
Cases were excluded from this study if non-luminal vol-
ume segmentation failed during automated image analysis.
Patients with ruptured AAA were excluded.
Table 1. Instructions for use for Nellix and contemporary endovascular aortic repair devices.
Nellix Cook Zenith Medtronic Gore
Non-aneurysmal AN length 10 mm 15 mm 10 mm 15 mm
Non-aneurysmal AN diameter 18e32 mm 18e32 mm 19e32 mm 19e29 mm
Maximum aortic blood ﬂow lumen diameter 60 mm e e e
Maximum common iliac artery diameter 8e35 mm 7.5e20 mm 8e25 mm 8e18.5 mm
Angle from neck to sac <60 <45 If AN length 10e15 mm, then 45
If AN length >15 mm, then 60
e
Angle from suprarenal aorta to neck e <60 If AN length 10e15 mm, then 60
If AN length >15 mm, then 75
60
AN ¼ aortic neck.
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Pre-operative CT images were acquired in the DICOM
(Digital Image and Communication in Medicine) format
from the hospital archive and analyzed using CT recon-
struction software (3Surgery; 3Mensio Medical Imaging B.V.,
Bilthoven, The Netherlands). All image sets had a slice
thickness of less than 3 mm and each image extended from
the thoracic inlet to the common femoral artery bifurcation.
Intravenous injection of 90 mL of Omnipaque 300 (Iohexol
300/Omnipaque 300; Sanoﬁ-Winthrop, New York, NY) was
used as standard. All measurements were taken orthogo-
nally to a semi-automatically installed central luminal line.
3D morphological assessment was performed utilising a
validated protocol4,13 with acceptable inter- and intra-
observer variability.
Outcome measures
The primary outcome measure for each of the four proce-
dure groups was compliance with anatomical instructions
for use supplied by the manufacturers of one EVAS system
(Endologix Nellix10) and three EVR devices (Cook Zenith,14
Medtronic Endurant,15 and Gore Excluder16). Criteria for
the Nellix IFU required a non-aneurysmal aortic neck length
of 10 mm, non-aneurysmal aortic neck diameter of 18e
32 mm, maximum aortic blood ﬂow lumen diameter of
60 mm, and common iliac artery diameter of 8e35 mm
(Table 1).Table 2. Demographics.
Infrarenal EVR
Male, n (%) 649 (88.9)
Mean age, n (%) 74.7  9.04
Smoking:
Non-smoker, n (%) 156 (21.4)
Current smoker, n (%) 350 (47.9)
Ex-smoker, n (%) 224 (30.7)
Hypertension, n (%) 495 (67.8)
IHD, n (%) 336 (46.0)
COPD, n (%) 183 (25.1)
Dyslipidaemia, n (%) 459 (62.9)
Diabetes, n (%) 104 (14.2)
Maximum patent AAA lumen diameter (mm) 48.74  17.65
Neck length (mm) 32.40  15.28
Neck diameter (mm) 25.89  4.32
Maximum CIA diameter (mm) 21.22  12.30
AAA ¼ abdominal aortic aneurysm; CIA ¼ common iliac artery; COPD ¼
repair; FEVR ¼ fenestrated endovascular repair; IHD ¼ ischaemic hearStatistical analysis
All analyses were performed using SPSS v.19 (IBM).
Dichotomous data were compared using the chi-squared or
Fisher’s Exact tests.RESULTS
The study population consisted of 776 patients who had an
identiﬁable AAA between January 2004 and July 2012 in
non-continuous series at two regional vascular units:
730/776 (94.1%) patients underwent infrarenal EVR, 6/776
(0.8%) underwent open repair, 27/776 (3.5%) underwent
FEVR and 13/776 (1.7%) underwent non-operative man-
agement (Table 2). Thirty-one patients were excluded
because automated volumetric processing was not possible.Morphological compliance with IFU for EVAS
Of all patients, 70.1% (544/776) were suitable for treatment
with Nellix under standard IFU of the Nellix system. This
differed signiﬁcantly (p < .001) across each procedure
group. Of those who underwent infrarenal EVR, 73.0%
(533/730) were compliant with Nellix IFU. Of those who had
undergone open repair, 50% (3/6) would have been
morphologically suitable for Nellix. Of patients treated by
FEVR, 7.4% (2/27) were within the limits of the Nellix IFU,
and 46.2% (6/13) of patients managed non-operatively
would have been morphologically suitable for Nellix (Fig. 2).OR FEVR Non-operative
6 (100) 24 (88.9) 7 (53.8)
72.7  7.97 73.5  7.73 80.1  7.20
0 (0) 5 (18.5) 1 (0.77)
3 (50.0) 7 (25.9) 5 (38.5)
3 (50.0) 15 (55.5) 7 (53.8)
5 (83.3) 22 (81.5) 12 (92.3)
2 (33.3) 17 (62.9) 8 (61.5)
1 (8.3) 7 (25.9) 5 (38.5)
4 (66.7) 21 (77.8) 10 (76.9)
0 (0) 0 (0) 1 (0.8)
46.07  11.15 43.43  11.02 48.69  11.86
15.03  14.16 2.63  4.76 15.61  18.83
29.40  4.67 38.51  9.12 31.04  8.15
17.10  2.95 17.32  5.58 21.48  7.08
chronic obstructive pulmonary disease; EVR ¼ endovascular aortic
t disease; OR ¼ open repair.
Figure 2. Differing suitability for Nellix among four groups of pa-
tients. FEVR ¼ fenestrated endovascular repair. Figure 4. Limitations of each component of Nellix instructions for
use (IFU) in patients undergoing endovascular aortic repair (EVR).
AAA ¼ abdominal aortic aneurysm; CIA ¼ common iliac artery.
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current EVR devices
Nellix was more widely applicable than current EVR devices:
497/730 (68.1%) of the infrarenal EVR group were
morphologically compliant with the Medtronic Endurant
device IFU (p ¼ .04), 379/730 (51.9%) compliant with the
IFU for the Cook Zenith device (p < .001), and 214/730
(29.3%) for the Gore C3 Excluder (p < .001) (Fig. 3). Of the
subgroup of patients treated by EVR outside device IFU for
existing endografts, Nellix also appeared a useful option:
116/233 (49.8%) of patients who underwent EVR outside
the IFU for the Medtronic Endurant device were compliant
with IFU for Nellix, 215/351 (61.3%) of patients treated by
EVR outside the IFU for the Cook Zenith device would have
been compatible with IFU for Nellix, and 347/516 (67.2%)
treated by EVR outside of the IFU for the Gore Excluder
would have been compatible with the IFU for Nellix.
Morphological compliance with each Nellix IFU component
in each procedure group
Infrarenal EVR: The maximum AAA patent lumen diameter
was suitable for Nellix in only 615/730 (84.2%) cases, rep-
resenting the most common barrier to the use of Nellix
(Fig. 4, Table 2). Neck length was within the IFU for Nellix in
698/730 (95.6%) cases, neck diameter in 687/730 (94.1%)Figure 3. Nellix instructions for use (IFU) compliance compared
with current endovascular aortic repair (EVR) devices in patients
from all four groups (n ¼ 776). FEVR ¼ fenestrated endovascular
repair.cases, neck angulation in 716/730 (98.1%) cases, and
maximum common iliac artery diameter in 706/730 (96.6%)
cases (Table 2).
Open repair patients: Neck length and neck diameter
were suitable for Nellix in 4/6 (66.7%) cases. The maximum
AAA patent lumen diameter fell within Nellix IFU in 5/6
(83.3%) cases and maximum common iliac artery diameter
was suitable for Nellix in all cases.
FEVR repair patients: Neck length was within the limits
of Nellix IFU in 2/27 (7.4%) cases and neck diameter was
suitable for Nellix in 10/27 (37.0%) cases. Twenty-ﬁve of
twenty-seven (92.6%) cases had a suitable maximum AAA
patent lumen diameter for Nellix, and the maximum com-
mon iliac artery diameter was compatible with Nellix IFU in
26/27 (96.3%).
Non-operative patients: Neck length was compatible
with Nellix in 7/13 (53.8%) cases. Aneurysm neck diameter
was suitable for Nellix in 9/13 (69.2%) cases, and the
maximum AAA patent lumen diameter was within Nellix IFU
in 11/13 (84.6%) cases. All cases were found to have a
maximum common iliac artery diameter suitable for Nellix.DISCUSSION
Nellix technology was widely applicable in a contemporary
series of patients with infrarenal AAA, and the main ﬁnding
of this study was that 70% of all aneurysms assessed were
suitable for treatment within the device’s IFU. Nellix
appeared to be applicable to a wider range of aortic
morphology than EVR devices currently in use. A notable
ﬁnding was that many patients who had undergone EVR
outside the IFU of current stent-grafts would have been
suitable for EVAS within the Nellix device IFU. This ﬁnding is
of particular importance in light of the higher incidence of
sac expansion observed in patients treated by EVR outside
manufacturers’ IFU.17,18
Individual assessment of each morphological criterion
revealed that the most common obstacle to the use of
Nellix was the presence of a large maximum patent lumen
diameter within the AAA sac. Device development to enable
relaxation of this criterion therefore represents an
444 A. Karthikesalingam et al.important area for future generations of this technology.
Conversely, wide aneurysm neck diameter, short neck
length, increased neck angulation or a large common iliac
artery diameter were rarely obstacles to the potential
deployment of a Nellix device. These features are often a
considerable challenge for modern EVR technology,19e23
and patients with large AAA remain a considerable chal-
lenge. It has been suggested that morphological hostility in
these cases might be attributable to the increasing wall
stress present at greater maximal aneurysm diameter,
which leads to morphological deterioration.24 It has previ-
ously been shown that large AAA diameter is the greatest
impediment to the suitability for traditional endovascular
therapy,25 whereas the presence of sac thrombus is of
greater importance for EVAS. The Nellix device cannot
currently be utilised in AAA in which the maximum patent
lumen diameter exceeds 60 mm, as each endobag has a
ﬁnite capacity for expansion to obliterate the aneurysm sac
and this may limit its use in larger diameter aneurysms at
present.
Almost half (46.2%) of patients managed non-
operatively were morphologically suitable for Nellix. Nel-
lix might offer a compassionate solution for this group,
but the selection of patients for non-operative manage-
ment is often made for reasons other than aneurysm
morphology.18 Extensive medical comorbidity and patient
preference is usually the dominant factor in non-operative
management of large AAA, and in such cases anatomical
suitability for novel endovascular devices may be of limited
relevance.
Nellix was morphologically applicable in most infrarenal
AAAs and might be of greatest use in patients that currently
undergo EVR outside the IFU for contemporary stent-grafts,
of whom many were suitable for Nellix. However, this
beneﬁt did not extend to patients with juxtarenal AAA.
Patients currently undergoing open AAA repair with revas-
cularisation of renal or visceral vessels would not have been
treatable within the current limitations of Nellix, and this
restriction applied equally to many patients selected for
FEVR. The further development of Nellix for use in these
more complex aneurysms is likely to follow evidence of its
safety and efﬁcacy in infrarenal AAA.
Clinical data are required to describe the performance of
Nellix in terms of its procedural complexity, short-term
morbidity, mid-term sequelae, and long-term safety.
Currently, reintervention is necessary in 20% of EVR pa-
tients over 5 years,6 with the majority entailing minimally
invasive endovascular procedures with little morbidity.26 It
remains to be seen how Nellix technology will compare
with this benchmark, particularly with regard to the need
for surveillance and options for reintervention after aneu-
rysm sealing. Estimates of the applicability of Nellix in non-
operative, FEVR and open surgery patients should be
interpreted with caution; further study is required in these
populations and detailed, case-speciﬁc evaluation is
needed before usage of the device can be considered.
Most notably, clinical data are currently lacking for this
device.CONCLUSION
Emerging Nellix technology was widely applicable in a
contemporary series of patients with AAA, and may be
particularly feasible in infrarenal AAA treated by EVR
outside existing devices’ IFU. The major limitation to the use
of Nellix is currently the maximum patent lumen diameter
of large AAA. Further studies are required to document the
clinical performance of Nellix and its longer-term sequelae.
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